UNSPSC 51432307: Pratosartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C25H26N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66VLQ6E6DL. The term PRATOSARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., no. 1.2002, list 47. ). Most nations schedule pratosartan under HS 29339990 and SITC 51577. As of Q4 2014, PRATOSARTAN remains the US FDA Preferred Term for this commodity. Pratosartan bears US NLM identifiers UMLS ID C2347659 and NCI Concept Code C72935.

SMILES: CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)CCCCC2=O.

UNSPSC 51432307 Pratosartan is a Commodity code for a specific antihypertensive pharmaceutical product, though state and local governments purchase this ingredient primarily as part of broader advanced life support and emergency medication supply contracts rather than as an isolated drug. The code sees solicitation activity from fire rescue departments, state health agencies, and cooperative purchasing alliances acquiring emergency pharmaceuticals for clinical use. Issuing bodies include municipal fire departments (like Tampa Fire Rescue), state health commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance). These entities procure not only pratosartan but broader medication inventories for emergency response, pharmacy benefit programs, and multi-jurisdiction distribution networks.

Geographic activity is concentrated in Florida, Texas, and Minnesota based on recent opportunities. The City of Tampa issued an IFB (Bid No. 26P00188) due April 8, 2026, for advanced life support medications including labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue—a $40,000 estimated contract with a 5 percent SLBE bid discount—though pratosartan was not explicitly named in that solicitation. Texas Health and Human Services Commission issued an RFI (HHS0017013) in early April 2026 to explore direct-to-manufacturer prescription programs across multiple therapeutic categories. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products across participating states including Oregon, with awards effective July 1, 2026. The MMCAP procurement emphasizes pricing competitiveness (75 percent weight), cGMP and DSCSA compliance, and distribution through three authorized wholesalers, with a two-year contract term and optional extensions. None of the three opportunities explicitly identified pratosartan as a line item, suggesting limited visibility for this specific drug in recent state and local solicitations.